Vivo Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Vivo Capital’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-310,584	Closed	-$17M	–	66
2020 Q4	$17M	Sell	310,584 -550,064	-64%	-$20.1M	0.76%	31
2020 Q3	$19.7M	Hold	860,648	–	–	1.14%	22
2020 Q2	$18M	Hold	860,648	–	–	1.29%	19
2020 Q1	$12M	Buy	+860,648	New	+$17M	1.09%	26
2019 Q3	–	Sell	-786,712	Closed	-$11.8M	–	24
2019 Q2	$11.8M	Buy	+786,712	New	+$13.7M	1.11%	25

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vivo Capital's RCKT Position: Q1 2021 in Review

Vivo Capital sold out of Rocket Pharmaceuticals (RCKT) in Q1 2021, closing a stake of 310,584 shares — an estimated $17M sold.

Vivo Capital first reported a position in RCKT in Q2 2019 and held it in 5 quarters. The position peaked at $19.7M in Q3 2020. 173 funds tracked by Wall St. Rank hold RCKT as of Q1 2021.

Vivo Capital reported no remaining Rocket Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Vivo Capital sold 310,584 Rocket Pharmaceuticals shares in Q1 2021, an estimated $17M.
Vivo Capital first reported a position in Rocket Pharmaceuticals in Q2 2019 and held it in 5 quarters.
Vivo Capital's Rocket Pharmaceuticals position peaked at $19.7M in Q3 2020.
173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2021.

Based on Vivo Capital's 13F filing for Q1 2021, filed 17 May 2021.